Interpretation of Global Initiative for Chronic Obstructive Lung Disease 2025
LI Xueping
WANG Fengyan
LIANG Zhenyu
CHEN Rongchang
Abstract：The Global Initiative for Chronic Obstructive Lung Disease(GOLD)2025 was released on November 11,2024,with important updates on precision diagnosis,individualized treatment and multidisciplinary management.In terms of diagnosis and evaluation,GOLD 2025 recommends an evaluation process of combining clinical practice with pre-and post-bronchodilator spirometry,and recommends to use lung function tracking software to dynamically monitor the trajectory of lung function,and provides a more detailed introduction to the application of chest computed tomography(CT)in the quantitative evaluation of pulmonary emphysema and the scoring of airway mucus plugs,and suggests that chest CT has the potential to be an important tool for phenotypic recognition of chronic obstructive lung disease.In terms of treatment strategies,GOLD 2025 is more refined in the management of inhaled glucocorticoids,and clearly guides the blood eosinophil level to make decisions about the use and withdrawal of inhaled glucocorticoids,and GOLD 2025 is the first to introduce a new type of targeted drug,the inhaled dual PDE3/PDE4 inhibitor ensifentrine and a biological agent of dupilumab as maintenance treatment options for stable chronic obstructive lung disease.In terms of preventive measures,GOLD 2025 intensifies vaccination and climate adaptation recommendations.In terms of the management of complications,GOLD 2025 highlights the prevention and control of cardiovascular events and the stratified management of pulmonary hypertension.The above updates provide important guidance for the clinical diagnosis,treatment,and exploration of chronic obstructive lung disease.
Keywords：Chronic obstructive lung diseasePulmonary functionInterpretation of guideline
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 113-119 )